181 related articles for article (PubMed ID: 27259218)
1. [Glucuronidation of antitumour therapeutics--detoxification, mechanism of resistance or prodrug formation?].
Mróz A; Mazerska Z
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1462-77. PubMed ID: 27259218
[TBL] [Abstract][Full Text] [Related]
2. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
[TBL] [Abstract][Full Text] [Related]
3. [UDP-glucuronyltransferases in detoxification and activation metabolism of endogenous compounds and xenobiotics].
Fedejko B; Mazerska Z
Postepy Biochem; 2011; 57(1):49-62. PubMed ID: 21735820
[TBL] [Abstract][Full Text] [Related]
4. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases.
Zhou J; Zhang J; Xie W
Curr Drug Metab; 2005 Aug; 6(4):289-98. PubMed ID: 16101569
[TBL] [Abstract][Full Text] [Related]
5. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation.
Burchell B; Brierley CH; Rance D
Life Sci; 1995; 57(20):1819-31. PubMed ID: 7475929
[TBL] [Abstract][Full Text] [Related]
6. UDP-glucuronosyltransferases.
King CD; Rios GR; Green MD; Tephly TR
Curr Drug Metab; 2000 Sep; 1(2):143-61. PubMed ID: 11465080
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of human UDP-glucuronosyltransferases responsible for the in-vitro glucuronidation of arctigenin.
Xin H; Xia YL; Hou J; Wang P; He W; Yang L; Ge GB; Xu W
J Pharm Pharmacol; 2015 Dec; 67(12):1673-81. PubMed ID: 26407805
[TBL] [Abstract][Full Text] [Related]
8. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions.
Ritter JK
Chem Biol Interact; 2000 Dec; 129(1-2):171-93. PubMed ID: 11154740
[TBL] [Abstract][Full Text] [Related]
9. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions.
Bock KW; Köhle C
Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
[TBL] [Abstract][Full Text] [Related]
11. The role of glucuronidation in drug resistance.
Mazerska Z; Mróz A; Pawłowska M; Augustin E
Pharmacol Ther; 2016 Mar; 159():35-55. PubMed ID: 26808161
[TBL] [Abstract][Full Text] [Related]
12. Natural and synthetic inhibitors of UDP-glucuronosyltransferase.
Grancharov K; Naydenova Z; Lozeva S; Golovinsky E
Pharmacol Ther; 2001 Feb; 89(2):171-86. PubMed ID: 11316519
[TBL] [Abstract][Full Text] [Related]
13. In vitro glucuronidation of the primary metabolite of 10-chloromethyl-11-demethyl-12-oxo-calanolide A by human liver microsomes and its interactions with UDP-glucuronosyltransferase substrates.
Liu X; Sheng L; Zhao M; Mi J; Liu Z; Li Y
Drug Metab Pharmacokinet; 2015 Feb; 30(1):89-96. PubMed ID: 25760535
[TBL] [Abstract][Full Text] [Related]
14. Activities of UDP-glucuronyltransferase, beta-glucuronidase and deiodinase types I and II in hyper- and hypothyroid rats.
van der Heide SM; Joosten BJ; Everts ME; Klaren PH
J Endocrinol; 2004 Jun; 181(3):393-400. PubMed ID: 15171687
[TBL] [Abstract][Full Text] [Related]
15. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs.
Li T; Zheng Y; Fu F; Ji H; Chen X; Zhao Y; Zhao D; Li N; Zhang L
Xenobiotica; 2011 Jul; 41(7):530-7. PubMed ID: 21524190
[TBL] [Abstract][Full Text] [Related]
16. Glucuronidation of haloperidol by rat liver microsomes: involvement of family 2 UDP-glucuronosyltransferases.
Narayanan R; LeDuc B; Williams DA
Life Sci; 2004 Apr; 74(20):2527-39. PubMed ID: 15010263
[TBL] [Abstract][Full Text] [Related]
17. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
[TBL] [Abstract][Full Text] [Related]
18. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.
Picard N; Ratanasavanh D; Prémaud A; Le Meur Y; Marquet P
Drug Metab Dispos; 2005 Jan; 33(1):139-46. PubMed ID: 15470161
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the zebrafish Ugt repertoire reveals a new class of drug-metabolizing UDP glucuronosyltransferases.
Wang Y; Huang H; Wu Q
Mol Pharmacol; 2014 Jul; 86(1):62-75. PubMed ID: 24728488
[TBL] [Abstract][Full Text] [Related]
20. Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.
Margaillan G; Rouleau M; Klein K; Fallon JK; Caron P; Villeneuve L; Smith PC; Zanger UM; Guillemette C
Drug Metab Dispos; 2015 Sep; 43(9):1331-5. PubMed ID: 26076694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
